
Yahoo · 30 de oct de 2026
Johnson & Johnson has released a string of positive trial readouts and product updates in oncology, immunology and MedTech, including data for subcutaneous amiv…
JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Últimos 235 días · 12/11/25 — 29/10/26
+58.74%
Precio
$ 30.280
Var. %
-0,13%
Volumen operado
11.309
Precio JNJ
US$ 273,55
Teórico (precio / ratio)
JNJ ÷ 15
US$ 18,24
Yield y fechas del subyacente vía Yahoo Finance. Ver calendario de dividendos.
Yield (USD)
2,0 %
Frecuencia (estimada)
Trim.
Próxima ex-date
23/11
Próximo pago
07/12
Cobro estimado (anual)
Dividendo anual USD ÷ ratio 15
USD 0,36
Sí, existe el CEDEAR de JNJ (Johnson & Johnson) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es JNJ.
El ticker del CEDEAR de Johnson & Johnson en Argentina es JNJ. La acción subyacente cotiza en NYSE con el símbolo JNJ.
El CEDEAR JNJ tiene un ratio de 15:1. Eso significa que 15 CEDEARs equivalen a 1 acción de JNJ.
El CEDEAR JNJ cotiza hoy a $ 30.280 en pesos argentinos, con una variación diaria de -0,13%.
Otros CEDEARs de Salud.

Yahoo · 30 de oct de 2026
Johnson & Johnson has released a string of positive trial readouts and product updates in oncology, immunology and MedTech, including data for subcutaneous amiv…

Yahoo · 30 de oct de 2026
On Halloween eve, the scariest thing an income investor can find is a yield that looks generous but is stressed. That payout is one the business can barely fund…

Yahoo · 30 de oct de 2026
Two health care ETFs track the same sector but own very different slices of it, and for retirees building a portfolio, that gap in biotech exposure and concentr…
Precio de cierre en pesos argentinos. Fuente: data912.
Cotización
US$ 19,28
vs teórico
+5,72%
Cotización MEP implícita
$ 1.570,54
Cotización
US$ 18,30
vs teórico
+0,35%
Cotización Cable implícita
$ 1.654,64
La acción subyacente JNJ (Johnson & Johnson) cotiza a US$ 273,55 en su mercado de origen (NYSE).
El precio teórico del CEDEAR JNJ se calcula dividiendo el precio de JNJ por el ratio (15). Hoy resulta en US$ 18,24.
En BYMA podés operar JNJ en pesos, JNJD en dólar MEP y JNJC en dólar cable. Cada modalidad refleja un tipo de cambio distinto.
En esta página encontrás un gráfico con el precio histórico del CEDEAR JNJ en pesos argentinos, con datos de data912.

Yahoo · 30 de oct de 2026
AbbVie beats Q3 earnings and revenue estimates as strong immunology and neuroscience sales drive growth, prompting a higher 2026 EPS outlook.

Yahoo · 30 de oct de 2026
AbbVie just handed shareholders their latest raise while your CD rate sits frozen, but the comparison between a guaranteed payment and a growing dividend gets c…

Yahoo · 30 de oct de 2026
Four companies have raised their dividends every single year for at least half a century, but not all of them carry the same risks heading into retirement. Here…

Yahoo · 30 de oct de 2026
J&J's MedTech growth slows in Q3 amid international market challenges and Abiomed weakness.

Yahoo · 30 de oct de 2026
Halozyme is poised for a Q3 earnings beat as strong demand for partnered drugs is likely to boost royalties and drive the top line.
Noticias vía Finnhub